Why Vir Biotechnology, Inc. (VIR) stock rose 14.4% intraday on Monday, November 9, 2026

Vir Biotechnology, Inc. (VIR) traded at $13.97 as of 2:31 PM ET, up 14.41% on Monday, November 9, 2026, on volume of 5,623,659 shares (2.9× its 3-month average); market value about $2.40B.

VIR was among the stocks moving 5% or more in an earlier update that day; by the close it was no longer moving that much.

What happened: primary sources

Events Nexqual found for VIR on Monday, November 9, 2026 or the trading day before (November 6, 2026):

• Nov 6, 2026: Schedule 13D/A: ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., 7.3% of shares, a 5%+ holder that may seek to influence the company source
  Quoted from the filing: “Each of AVF IX and AVF IX Overage acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. From November 3, 2026 to November 5, 2026, AVF IX and AVF IX Overage sold 347,819 shares and 448,356 shares respectively, of Common Stock for cash. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:…”
• Nov 9, 2026: SEC 8-K: Other material event source
  Quoted from the filing: “ECLIPSE 1 TLR Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting , in Denver, Colorado on November 8, 2026. ECLIPSE 1 enrolled a total of 124 patients, randomized 2:1, to receive monthly subcutaneous elebsiran and tobevibart or delayed treatment, with the delayed treatment group initiating therapy at Week 12. The trial enrolled a broad and diverse CHD…”
• Nov 9, 2026: HC Wainwright & Co.: Reiterated, Buy, price target $22

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on VIR

VIR stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 9, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:24 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt